Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

Background Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti‐IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response remain not completely defined. Object...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology Vol. 33; no. 5; pp. 918 - 924
Main Authors: Marzano, A.V., Genovese, G., Casazza, G., Fierro, M.T., Dapavo, P., Crimi, N., Ferrucci, S., Pepe, P., Liberati, S., Pigatto, P.D., Offidani, A., Martina, E., Girolomoni, G., Rovaris, M., Foti, C., Stingeni, L., Cristaudo, A., Canonica, G.W., Nettis, E., Asero, R.
Format: Journal Article
Language:English
Published: England 01.05.2019
Subjects:
Adult
Anti-Allergic Agents - therapeutic use
Biomarkers - blood
Chronic Disease
Female
Fibrin Fibrinogen Degradation Products - metabolism
Humans
Immunoglobulin E - blood
Italy
Male
Middle Aged
Omalizumab - therapeutic use
Recurrence
Retrospective Studies
Treatment Outcome
Urticaria - blood
Urticaria - drug therapy
Urticaria - physiopathology
Italy
ISSN:0926-9959, 1468-3083, 1468-3083
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti‐IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response remain not completely defined. Objectives To correlate baseline levels of two proposed biomarkers, total IgE (bIgE) and d‐dimer (bd‐dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal. Methods In this retrospective Italian multicentre study, clinical data were collected in 470 CSU patients, and bIgE and bd‐dimer were measured in 340 and 342 patients, respectively. Disease activity was determined by Urticaria Activity Score 7 (UAS7) at week 1 and 12 after omalizumab starting. Relapses were evaluated during a 2‐ and 3‐month interval after a first and a second course of treatment, respectively. Results bIgE correlated to a good response to omalizumab since levels were significantly higher in responders than non‐responders (P = 0.0002). Conversely, bd‐dimer did not correlate to response. There was no correlation between both bIgE and d‐dimer and either first or second relapse. Disease duration was significantly longer in patients who experienced either first or second relapse (P < 0.0001 and P = 0.0105, respectively), while baseline UAS7 correlated only to first relapse (P = 0.0023). Conclusions Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd‐dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.
Bibliography:None.
All authors declare no conflicts of interest.
Conflict of interest
Funding source
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.15350